Xenetic Biosciences Extends Research Agreement With University of Virginia For Advancement Of DNase-Based Oncology Platform
Xenetic Biosciences Extends Research Agreement With University of Virginia For Advancement Of DNase-Based Oncology Platform
Xenetic Biosciences 與維吉尼亞大學擴大研究協議,以推動基於DNase的腫瘤平台的發展
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications
公司繼續推動基於DNase的腫瘤項目,朝着多種適應症的臨床概念驗證研究邁進
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。